Cuffless blood pressure devices keep passing tests. Cardiologists still won't endorse them

A watch, a ring or an armband that reports a blood pressure number without squeezing your arm is an appealing product. It removes the one part of blood pressure measurement everybody dislikes, and it makes possible the thing a cuff cannot do at all — reading pressure continuously through a night's sleep, without waking the sleeper up.

On 25 February a scientific statement in the European Journal of Preventive Cardiology set out what these devices are, what they might eventually deliver, and why the authors are not prepared to recommend using their output to make a clinical decision [s1].

What "cuffless" actually covers

The phrase describes a heterogeneous group rather than a single technology. The statement describes devices that work primarily by measuring pulse wave propagation time or by analysing the pulse waveform, through either contact or non-contact sensors [s1]. Beyond the sensing method, the statement sorts the category along four further axes: continuous or intermittent, automated or manual, calibration-free or requiring calibration against a cuff or demographic data, and wearable or stationary [s1].

That diversity is the crux of the validation problem. The statement's position is that this range of designs requires validation protocols distinct from those developed for conventional cuff-based monitors, with specific requirements for each device category [s1].

The upside the statement does grant

The authors are not dismissive of the category's potential. They list several plausible clinical applications: widespread out-of-office blood pressure monitoring, unbiased assessment of circadian blood pressure patterns and blood pressure variability, improved detection of nocturnal hypertension, enhanced treatment adherence and long-term control, and continuous monitoring in hospital settings [s1]. They also note that a lower cost than conventional technology could support earlier detection of hypertension in resource-limited settings [s1].

And the sentence that governs

Having granted all of that, the statement declines to endorse clinical use. Because of insufficient accuracy validation, it does not recommend the use of cuffless devices in clinical decisions despite their potential interest — a position the authors describe as consistent with international guidelines, which do not recommend them for hypertension management [s1].

The obstacles listed are not small ones. They include developing standardised validation protocols, establishing normative blood pressure data, managing the burden on clinicians of handling very large volumes of readings, and advancing sensor technology, mathematical models and algorithms [s1].

A retraction, six weeks earlier

The state of the validation literature can be read directly. On 31 January 2026, European Heart Journal - Digital Health published a retraction of a paper titled "Validation of a popular consumer-grade cuffless blood pressure device for continuous 24 h monitoring" [s2]. The retracted article had appeared in the same journal on 29 April 2025 [s3].

The retraction notice itself records only that the article is retracted [s2]; it is not a source for what went wrong. What it establishes is narrower and still worth knowing: the published evidence supporting a specific consumer-grade cuffless device was withdrawn from the record within nine months of appearing in it.

Individual devices do pass tests

None of this means every cuffless device fails every assessment. A validation study published in the American Journal of Hypertension on 14 December 2025 tested a photoplethysmography-based cuffless upper-arm wearable monitor against the AAMI/ESH/ISO 81060-2:2018/Amd 1:2020 standard in 120 participants aged 20 and over, recruited to represent a range of ages and skin tones [s4]. The device met the standard's accuracy criteria [s4]. Subgroup analysis comparing participants aged 65 and over with younger participants, and lighter with darker skin tones classified by the Fitzpatrick system, found consistent accuracy across groups, with slight differences the authors said warrant further exploration [s4]. The cuffless design also produced faster readings with less variation across three averaged measurements [s4].

Two caveats sit inside that result. The device was calibrated against a clinically validated mercury sphygmomanometer before testing [s4] — calibration-dependence is one of the axes the scientific statement uses to sort the category [s1]. And the authors themselves conclude that larger-scale studies are warranted to corroborate their observations [s4].

How to hold the two findings together

There is no contradiction between a single device passing a validation standard and a scientific statement declining to recommend the category. They are answers to different questions.

A validation study asks whether one device, calibrated in one way, matched a reference measurement in one sample under specified conditions. The scientific statement asks whether the protocols used for that comparison are adequate to the technologies being tested, and concludes they are not yet — that the category needs validation requirements built for each device type rather than inherited from cuffs [s1].

For someone who owns one of these products, the practical distinction is between a number that is interesting and a number that should change something. The statement's position is that the evidence does not yet support the second use [s1]. It says nothing about whether the readings are worth looking at, and it explicitly identifies overnight and continuous measurement as the place where the technology could eventually add something a cuff cannot [s1].

What to watch

The statement names the missing pieces precisely, which makes progress legible. Watch for device-category-specific validation protocols, for published normative data on what cuffless readings look like in populations without hypertension, and for whether regulators or guideline bodies begin recognising any cuffless device for a defined clinical purpose rather than for general wellness use.

Sources

1. [s1] Cuffless Blood Pressure Monitoring Devices: Technical Foundations and Clinical Implications. European Journal of Preventive Cardiology, published online 25 February 2026. https://doi.org/10.1093/eurjpc/zwag058
2. [s2] Retraction of: Validation of a popular consumer-grade cuffless blood pressure device for continuous 24 h monitoring. European Heart Journal - Digital Health, 31 January 2026. https://doi.org/10.1093/ehjdh/ztag002
3. [s3] Validation of a popular consumer-grade cuffless blood pressure device for continuous 24 h monitoring. European Heart Journal - Digital Health, published online 29 April 2025 (retracted). https://doi.org/10.1093/ehjdh/ztaf044
4. [s4] Validation and Subgroup Analysis of the Accuracy of the Photoplethysmography-based Microlife Cuffless Upper-arm Wearable Blood Pressure Monitor. American Journal of Hypertension, published online 14 December 2025. https://doi.org/10.1093/ajh/hpaf238